Iqbal Javeed, Liu Zhongfeng, Deffenbacher Karen, Chan Wing C
Departments of Pathology and Microbiology, Center for Lymphoma and Leukemia Research, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA.
Best Pract Res Clin Haematol. 2009 Jun;22(2):191-210. doi: 10.1016/j.beha.2009.05.001.
The classification of lymphoid malignancies has evolved from a purely morphological scheme to the current WHO (World Health Organization) classification, which takes into consideration histological, immunophenotypic, genetic and clinical information. DNA microarray technology enables the simultaneous determination of the expression levels for thousands of genes (gene expression profile; GEP) and provides a powerful approach for investigating lymphoma biology and improving disease classification. Distinct molecular signatures for many lymphomas, as well as novel lymphoma subtypes have been identified. Molecular prognosticators have also been constructed. Many of the molecular subgroups of lymphoma also show distinct patterns of genetic abnormalities. We also briefly review the application of other genome-wide techniques to the study of lymphomas, such as high resolution array comparative genomic hybridization (aCGH) and next-generation sequencing, and how these technologies will complement each other in improving our understanding of the pathobiology of lymphoma. Specific therapeutic targets will likely emerge from the increased insight into the molecular pathogenesis of the different lymphomas, thus illustrating the utility of these global studies in advancing disease management strategies.
淋巴系统恶性肿瘤的分类已从单纯的形态学方案发展到目前的世界卫生组织（WHO）分类，该分类考虑了组织学、免疫表型、遗传学和临床信息。DNA微阵列技术能够同时测定数千个基因的表达水平（基因表达谱；GEP），为研究淋巴瘤生物学和改进疾病分类提供了强有力的方法。已确定了许多淋巴瘤的独特分子特征以及新的淋巴瘤亚型。还构建了分子预后指标。淋巴瘤的许多分子亚组也表现出不同的基因异常模式。我们还简要回顾了其他全基因组技术在淋巴瘤研究中的应用，如高分辨率阵列比较基因组杂交（aCGH）和下一代测序，以及这些技术如何相互补充以增进我们对淋巴瘤病理生物学的理解。对不同淋巴瘤分子发病机制的深入了解可能会产生特定的治疗靶点，从而说明这些全面研究在推进疾病管理策略方面的实用性。
